GlassScriptPhysician profile
Christopher Szoke
NPI 1497852396
$3,265.42
in general payments reported to CMS, 2019-2025
15 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $269 · 2022: $212 · 2023: $2,503 · 2024: $39.94 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,025 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.92 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,025.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $205.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $1,715.97 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Astrazeneca Pharmaceuticals LP | $445.28 | 2021-2023 | Breztri, Farxiga |
| Medtronic, INC. | $323.55 | 2021-2023 | Minimed 780g, Minimed 770g |
| Novo Nordisk INC | $240.72 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Dexcom, INC. | $117.71 | 2022-2023 | Dexcom G7 Gss (161) |
| Embecta Corp. | $114.33 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Mannkind Corporation | $59.40 | 2021 | |
| Lilly USA, LLC | $47.24 | 2021-2025 | Zepbound, Mounjaro |
| Sequel Med Tech, LLC | $37.76 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $37.59 | 2022 | |
| Pfizer INC. | $32.90 | 2023 | |
| Ascensia Diabetes Care US INC. | $27.82 | 2022 | |
| Insulet Corporation | $26.63 | 2021 | |
| Abbvie INC. | $21.72 | 2023 | |
| Cequr Corporation | $16.80 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Szoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.